WO/2014/094844 LOCALIZED DISINFECTION SYSTEM FOR LARGE WATER BODIES||WO||26.06.2014|
||PCT/EP2012/076170||CRYSTAL LAGOONS (CURACAO) B.V.||FISCHMANN, Fernando Benjamin|
The present disclosure relates to a method for controlling the microbiological properties of a portion of water within a large body of water by treating such zone with chemical agents, according to the temperature of the water, its salinity, its dilution power and the diffusion of chemicals within the large water body.
WO/2013/180596 "DOLG M3" TACTICAL GUN BELT||WO||05.12.2013|
||PCT/RU2013/000102||KHARLAMPOV, Vladimir Vladimirovich||KHARLAMPOV, Vladimir Vladimirovich|
The invention relates to gun technology and, specifically, to belts for a gun used by special detachments. The tactical gun belt comprises a length-adjustable sling in the form of a loop, a carrying-sling clamp on the barrel, a rapidly detachable element for fixing to the gun barrel block and an element for fixing to the gun butt, or an element for fixing to the rear carrying-sling clamp on the gun breech, a sling-adjustment unit, and a tightening strap which passes through the sling-adjustment unit, wherein one end of said sling is fixed via the rapidly detachable element to the carrying-sling clamp on the barrel, and the other end is left free. The novelty resides in the fact that the belt additionally comprises a rapid-adjustment unit through which the sling in the form of a loop passes. Such an embodiment of a gun belt makes it possible very rapidly to adjust the length of the belt and to incorporate a large adjustment margin of the basic loop, which makes it possible to transform and use the belt on virtually any type of personal small arms: on submachine guns, automatic rifles, sniper rifles, smooth-bore guns, etc.
WO/2013/174847 LOW -MOLECULAR -WEIGHT BIOTECHNOLOGICAL CHONDROITIN 6 - SULPHATE FOR PREVENTION OF OSTEOARTHRITIS||WO||28.11.2013|
||PCT/EP2013/060471||GNOSIS S.P.A.||MIRAGLIA, Niccolò|
Disclosed is a low-molecular-weight (1000-5000 daltons) chondroitin sulphate (CS) produced by chemical sulphation and subsequent depolymerisation of a non-sulphated chondroitin backbone obtained with biotechnology techniques. The CS described is substantially monosulphated, mainly at the 6-position, with very little sulphation at the 4-position, and with a mono/disulphated disaccharide ratio and charge density similar to those of natural CS. Said biotechnological chondroitin 6-sulphate (C6S) is useful in the treatment and prevention of osteoarthritis and in acute and chronic inflammatory processes.
WO/2013/164315 A DELAYED RELEASE DRUG FORMULATION||WO||07.11.2013|
||PCT/EP2013/058921||TILLOTTS PHARMA AG||BRAVO GONZÁLEZ, Roberto Carlos|
Delayed release of a drug to the colon is achieved from a delayed release formulation comprising a core and a coating for the core. The core comprises a drug and the coating comprises an inner layer and an outer layer. The outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria, and a second polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a third polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said third polymeric material being selected from an at least partially neutralised polycarboxylic acid and a non-ionic polymer. In embodiments in which the third polymeric material is a non-ionic polymer, the inner layer comprises at least one of a buffer agent and a base. Advantages of formulations according to the present invention include accelerated release of the drug when exposed to colonic conditions and reduction or elimination of a food and/or alcohol effect on drug release after administration.
WO/2013/164316 A DELAYED RELEASE DRUG FORMULATION||WO||07.11.2013|
||PCT/EP2013/058923||TILLOTTS PHARMA AG||BRAVO GONZÁLEZ, Roberto Carlos|
Delayed release of a drug to the colon is achieved from a delayed release formulation comprising a core and a coating for the core. The core comprises a drug and the coating comprises an outer layer and at least one layer between the core and the outer layer selected from the group consisting of an isolation layer and an inner layer. The outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria, and a second polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a third polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said third polymeric material being selected from an at least partially neutralised polycarboxylic acid and a non-ionic polymer. In embodiments in which the third polymeric material is a non-ionic polymer, the inner layer comprises at least one of a buffer agent and a base. The isolation layer comprises a non-ionic polymer which is soluble in intestinal fluid or gastrointestinal fluid. The outer is applied directly to the inner layer or the isolation layer using a coating preparation formed by combining the first polymeric material in an aqueous medium with a second polymeric material in an organic medium. Advantages of formulations according to the present invention include accelerated release of the drug when exposed to colonic conditions and reduction or elimination of a food and/or alcohol effect on drug release after administration.
WO/2013/165247 METHOD OF MANUFACTURING A TUBE SHEET AND HEAT EXCHANGER ASSEMBLY FOR A POOL REACTOR OR POOL CONDENSER; CORRESPONDING TUBE SHEET AND HEAT EXCHANGER ASSEMBLY||WO||07.11.2013|
||PCT/NL2013/050331||STAMICARBON B.V.||SCHEERDER, Alexander Aleida Antonius|
The present application relates to a method of manufacturing a tube sheet (7) and heat exchanger assembly for a pool reactor or pool condenser for use in the production of urea from ammonia and carbon dioxide, wherein the method comprises manufacturing of the tube sheet (7) from a carbon steel material grade and providing said tube sheet (7) with corrosion protective layers (8, 9) of an austenitic- ferritic duplex stainless steel grade, wherein the heat exchanger comprises at least one U-shaped tube (13) of an austenitic-ferritic duplex stainless steel grade, the method further comprises inserting at least two sleeves (11) of an austenitic-ferritic duplex stainless steel grade through the tube sheet (7) such that both ends of the sleeve (11) extend in a direction away from the tube sheet (7), the method further comprises connecting the sleeves (11), at least the opposing ends thereof, to at least the protective layers (8,9) of the tube sheet (7) and finally, connecting both ends of the at least one U-shaped tube (13) to the respective sleeves (11).
WO/2013/160919 A COMPOSITE SLIDING GASKET FOR HIGH-PRESSURE JOINTS||WO||31.10.2013|
||PCT/IT2012/000118||COES COMPANY SRL||BIZZARRINI, Giuseppe|
A composite sliding gasket (7) for joints of high- pressure pipes is basically formed by a rubber part (9) and by a rigid ring (8) - having the function of flange - that is designed to draw the gasket (7) itself from a resting position or seat (10) to a working position or seat (11) by an external pipe or hole (5) that is axially fitted on an internal pipe or barbed fitting (4). Compression of the rubber part (9) of the gasket (7), which guarantees fluid tightness, is obtained thanks to the presence of a purposely provided conical area (12) pre-arranged on the barbed fitting (4) between said resting seat (10) and said working seat (11) - Said gasket (7) is basically constituted by a rubber ring (9) fixedly coupled to a coaxial flange made of rigid material (8) of plastic or metal or some other suitable material, said gasket (7) being designed to seal a coupling with play between the hollow shaft or internal pipe (4) and the hole (5) within which a pressurized fluid can flow.
WO/2013/160129 METHOD AND SYSTEM FOR THE ADMINISTRATION OF A PULMONARY SURFACTANT BY ATOMIZATION||WO||31.10.2013|
||PCT/EP2013/057744||CHIESI FARMACEUTICI S.P.A.||DELLACA', Raffaele|
The method and system according to preferred embodiments of the present invention allows optimizing the dispensing of aerosol medicaments. In particular the system according to a preferred embodiment of the present invention allows the administration of an exogenous pulmonary surfactant to very young patients (e.g. preterm neonates). A catheter (101) conveys atomized surfactant directly to the retro-pharyngeal region in order to increase efficiency of the medicament administration without being invasive: this is particularly important for very young patients, such as pre-term born neonates suffering from neonatal Respiratory Distress Syndrome (nRDS). It is possible to couple the catheter with a rigid scaffolding (e.g. metallic) to increase stiffness of the device and to improve easiness of positioning operations. In a preferred embodiment of the present invention the delivery of the atomized medicament is done by means of an air blasting technique.
WO/2013/163560 DIRECT VOLUME-CONTROLLING DEVICE (DVCD) FOR RECIPROCATING POSITIVE-DISPLACEMENT PUMPS||WO||31.10.2013|
||PCT/US2013/038440||CHECKPOINT FLUIDIC SYSTEMS INTERNATIONAL, LTD.||ELLIOTT, Andrew C.|
A volume control device having a housing with an inlet passage, an outlet passage, and an internal chamber communicating with the inlet and outlet passages. An accumulator is movably positioned within the internal chamber and substantially conforms with walls of the internal chamber, the accumulator including an internal passage allowing fluid flow therethrough. An one-way valve is positioned in the internal passage of the accumulator where the valve is biased in a closed position and an adjustable seat is positioned within the housing internal chamber between the accumulator and the housing outlet passage. A positioning mechanism engages the housing and adjustable seat whereby the position of the adjustable seat within the housing internal chamber may be adjustably fixed.
WO/2013/163633 ANTI-GCC ANTIBODY MOLECULES AND USE OF SAME TO TEST FOR SUSCEPTIBILITY TO GCC-TARGETED THERAPY||WO||31.10.2013|
||PCT/US2013/038542||MILLENNIUM PHARMACEUTICALS, INC.||FRANK, Helen, Alison|
Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The invention also provides diagnostic methods for identifying patients who should receive a GCC-targeted therapy utilizing the anti-GCC antibodies provided herein. The anti-GCC antibody molecules are useful as naked antibody molecules and as components of immunoconjugates. Accordingly, in another aspect, the invention features immunoconjugates comprising an anti-GCC antibody molecule described herein and a therapeutic agent or label. The invention also features methods of using the anti-GCC antibody molecules and immunoconjucates described herein, e.g., for detection of GCC and of cells or tissues that express GCC. Such methods are useful, inter alia, for diagnosis, prognosis, imaging, or staging of a GCC-mediated disease. Accordingly, in some aspects, the invention features methods of identifying a subject for treatment with a GCC- targeted therapy, e.g., an anti-GCC antibody therapy, e.g., an immunoconjugate comprising an anti-GCC antibody conjugated with a therapeutic agent.